Lux Biosciences, Inc. Report issue

For profit Phase 3 Phase 4
Founded: Jersey City NJ United States (2005)
Status: Defunct (2014)

Organization Overview

First Clinical Trial
2007
NCT00404742
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Chief Medical Officer, Lux Biosciences, Inc. | Luxbiotech

Active Ingredients

Drugs in Phase 4 Trials (3)

pantothenic acid (1 trial)

Polydimethylsiloxane (1 trial)

thiamine (1 trial)

Drugs in Phase 3 Trials (2)

lx201 (2 trials)

voclosporin (Lupkynis) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Corneal Diseases (Phase 3)

Dry Eye Syndromes (Phase 1)

Iridocyclitis (Phase 3)

Keratoconjunctivitis (Phase 1)

Keratoconjunctivitis Sicca (Phase 1)

Panuveitis (Phase 3)

Pars Planitis (Phase 3)

Uveitis (Phase 3)

Uveitis, Anterior (Phase 3)

Uveitis, Intermediate (Phase 3)

Uveitis, Posterior (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 5